Beacon Hospital announced completion of its first ablation case performed using the Medtronic Affera™ Mapping and Ablation System. The surgery was performed by Prof. Jonathan Lyne, Consultant Cardiologist and Electrophysiologist along with Beacon Hospital’s Cath Lab team.
As well as being the first hospital in Ireland and the UK to perform the pioneering treatment, Beacon Hospital is among the first five hospitals worldwide to carry out the procedure.
One in four people over the age of 50 are at risk of developing atrial fibrillation (AF), the most common atrial arrhythmia (fast, abnormal heart rhythms). It occurs more frequently in those with underlying heart disease. Without early intervention, AF can progress and is associated with a higher rate of cardiovascular admissions, heart failure hospitalisation, and mortality, along with a reduced quality of life.
The new technology maps and ablates (removes) atrial arrhythmias and provides real-time feedback through its intuitive mapping and navigation software.
Michael Cullen, CEO of Beacon Hospital said: “We are proud to provide this new treatment option to our patients and be the first in Ireland and the UK to do so. With world-leading technology, treatments and consultants, we’re committed to providing the very best care and outcomes for our cardiac patients.”
Prof. Jonathan Lyne, Consultant Cardiologist and Electrophysiologist at Beacon Hospital said: “The first procedures went very well, and our patients are now recovering. As atrial fibrillation is the most common arrhythmia present in patients, this new procedure is a game changer for our team as it allows for more flexibility during an ablation procedure.”
Alice Griffin, Head of Cardiac Services at Beacon Hospital said: “It is an exciting time to be leading Beacon Hospital’s Cardiac Departments as we continue to invest and expand for our patients and medical teams. By providing our patients with the option of being treated with the Sphere-9 Catheter, we can potentially improve their outcomes, reduce the need to redo cases and offer more efficient procedures at our hospital. It is also great for our staff in terms of training and professional development”.
The Affera™ Mapping and Ablation System includes the Sphere-9™ Catheter and the Affera™ Prism-1 Mapping Software.
Studies to date show that treatment with the Sphere-9 Catheter provided 85% one-year freedom from recurrence of atrial arrhythmias. In all paroxysmal and persistent AF patients who underwent an ablation, 78% of both cohorts remained free from all atrial arrhythmias at the conclusion of the study. The study achieved its primary safety endpoint of 0.6%, including zero incidences of atrio-esophageal fistula, coronary spasm, pulmonary vein stenosis, and phrenic nerve injury.